Quantifying the burden of disease and perceived health state in patients with Hereditary Angioedema in Japan: Patient-Reported Outcomes study

Quantifying the burden of disease and perceived health state in patients with Hereditary Angioedema in Japan: Patient-Reported Outcomes study - HAE-PRO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042425

Enrollment

Registered

2020-11-16

Start date

2021-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Angioedema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subject has been diagnosed with HAE by a physician and is 18 years or older in age

Exclusion criteria

Exclusion criteria: Currently participating or planning to participate in any clinical trials and receiving any investigational agents for HAE treatment.

Design outcomes

Primary

Measure	Time frame
To assess the health-related quality of life of Japanese patients with HAE using AE-QOL	—

Secondary

Measure	Time frame
1) To assess disease activity and mental health using AAS and HADS 2) To assess general health status and work productivity using SF-12 and WPAI	—

Countries

Japan

Contacts

Public ContactMiwa Kishimoto

Takeda Pharmaceutical Company Limited Japan Medical Office

miwa.kishimoto@takeda.com080-2171-9043

Outcome results